Revolution Medicines' Daraxonrasib Shows Survival Benefit In Phase 3 Pancreatic Cancer Trial; Eyes FDA Submission

Benzinga Newsdesk www.benzinga.com Positive 88.4%

Neg 0% Neu 0% Pos 88.4%

Comments

No comments yet. Be the first!